ARID1A and posterior cortical atrophy: While ARID1A mutations are infrequent in PCa, studies have shown that low ARID1A expression is associated with adverse disease outcomes, including increased inflammation and immune suppression (Li et al, 2022), suggesting that perhaps patients with low ARID1A expression may benefit from ICB.